Home > Referring Physicians >
(CONSCIOUS-3)A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasopasm-Related Morbidity and All Cause Mortality in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Treated by Enedovascular Coiling.
A study to determine the effects (good and bad) of supplements: selenium, vitamin E, and selenium plus vitamin E, in preventing or reducing the occurrence of prostate cancer.
[185500-3] Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function
6 Minute Walk Test in a Pediatric Population: Methods and Reference Values
A 12-week, multicenter, randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administrated orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures
A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin for the Treatment of Chronic Central Neuropathic Pain after Spinal Cord Injury
A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled Everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de nove liver transplant recipients
A 24-month Multicenter, Randomized, Open-label Non- Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Certican with Reduced Neoral versus 3.0 g MMF with Standard Dose Neoral in De Novo Heart Transplant Recipients
A 24-Month, Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis
A 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group, international Phase III study with a 24-week extension period to evaluate the safety and efficacy of dapagliflozin 10 mg daily in patients with type 2 Diabetes who have inadequate glycemic control on a DPP-4 inhibitor (sitagliptin) alone or in combination with metformin